Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery.

Tumor organoids are 3D cultures of cancer cells that can be derived on an individual patient basis with a high success rate. This creates opportunities to build large biobanks with relevant patient material that can be used to perform drug screens and facilitate drug development. The high take rate will also allow side-by-side comparison to evaluate the translational potential of this model system to the patient. These tumors-in-a-dish can be established for a variety of tumor types including colorectal, pancreas, stomach, prostate, and breast cancers. In this review, we highlight what is currently known about tumor organoid culture, the advantages and challenges of the model system, compare it with other pre-clinical cancer models, and evaluate its value for drug development.

[1]  H. Janssens,et al.  Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids , 2016, European Respiratory Journal.

[2]  V. Gulmans,et al.  Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration , 2016, Current opinion in pulmonary medicine.

[3]  Carlos F. Lopez,et al.  An unbiased metric of antiproliferative drug effect in vitro , 2016, Nature Methods.

[4]  Asif U. Tamuri,et al.  Genome sequencing of normal cells reveals developmental lineages and mutational processes , 2014, Nature.

[5]  Calvin J Kuo,et al.  Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche , 2009, Nature Medicine.

[6]  Andreas Schlicker,et al.  Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. , 2014, Cell reports.

[7]  Tetsuya Nakamura,et al.  Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes , 2016, Journal of Gastroenterology.

[8]  Hayley E. Francies,et al.  Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.

[9]  B. Dutrillaux,et al.  Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. , 2007, Cancer research.

[10]  V. Baekelandt,et al.  rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice. , 2016, American journal of respiratory and critical care medicine.

[11]  W. Bodmer,et al.  Cancer cell lines for drug discovery and development. , 2014, Cancer research.

[12]  H. Clevers,et al.  Single Lgr5 stem cells build crypt–villus structures in vitro without a mesenchymal niche , 2009, Nature.

[13]  Andrea Sottoriva,et al.  Defining Stem Cell Dynamics in Models of Intestinal Tumor Initiation , 2013, Science.

[14]  M. Gottesman,et al.  Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer. , 2004, Molecular interventions.

[15]  Hans Clevers,et al.  Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. , 2011, Gastroenterology.

[16]  David Mittelman,et al.  Lentiviral and targeted cellular barcoding reveals ongoing clonal dynamics of cell lines in vitro and in vivo , 2014, Genome Biology.

[17]  M. Rubin,et al.  High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. , 2014, Cancer research.

[18]  V. Torri,et al.  Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas , 2015, Clinical Cancer Research.

[19]  Xiao-Jun Ma,et al.  Role of three‐dimensional matrix stiffness in regulating the chemoresistance of hepatocellular carcinoma cells , 2015, Biotechnology and applied biochemistry.

[20]  G. Milano,et al.  Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Hans Clevers,et al.  Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening , 2016, eLife.

[22]  H. Clevers,et al.  Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis , 2016, Science Translational Medicine.

[23]  Hans Clevers,et al.  Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver , 2015, Cell.

[24]  Hans Clevers,et al.  A functional CFTR assay using primary cystic fibrosis intestinal organoids , 2013, Nature Medicine.

[25]  A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer , 2011, Molecular Cancer Therapeutics.

[26]  John W. Cassidy,et al.  A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds , 2016, Cell.

[27]  Chris Albanese,et al.  ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. , 2012, The American journal of pathology.

[28]  M. Junttila,et al.  Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.

[29]  Toshio Uraoka,et al.  A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis. , 2016, Cell stem cell.

[30]  Hans Clevers,et al.  Designer matrices for intestinal stem cell and organoid culture , 2016, Nature.

[31]  Davide Prandi,et al.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. , 2017, Cancer discovery.

[32]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[33]  Hans Clevers,et al.  Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.

[34]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[35]  E. Cuppen,et al.  Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures , 2014, Cell.

[36]  Hans Clevers,et al.  Organoid Cultures Derived from Patients with Advanced Prostate Cancer , 2014, Cell.

[37]  Hans Clevers,et al.  Interrogating open issues in cancer precision medicine with patient-derived xenografts , 2017, Nature Reviews Cancer.

[38]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[39]  Hans Clevers,et al.  Sequential cancer mutations in cultured human intestinal stem cells , 2015, Nature.

[40]  P. Sorger,et al.  Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.

[41]  R. Bernards,et al.  DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance? , 2016, Cancer discovery.

[42]  C. Begley,et al.  Drug development: Raise standards for preclinical cancer research , 2012, Nature.

[43]  Jorge S Reis-Filho,et al.  Genetic heterogeneity and cancer drug resistance. , 2012, The Lancet. Oncology.

[44]  Hans Clevers,et al.  Lgr5(+) liver stem cells, hepatic organoids and regenerative medicine. , 2013, Regenerative medicine.

[45]  J. Beekman,et al.  Novel opportunities for CFTR-targeting drug development using organoids , 2013, Rare diseases.

[46]  Catherine L. Worth,et al.  Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors , 2017, Nature Communications.

[47]  Gordon Keller,et al.  Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids , 2015, Nature Medicine.

[48]  Hans Clevers,et al.  Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases , 2015, Proceedings of the National Academy of Sciences.

[49]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[50]  Chad A Shaw,et al.  A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. , 2013, Cancer research.

[51]  D. Aust,et al.  Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. , 2012, The Journal of surgical research.

[52]  Hans Clevers,et al.  In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. , 2015, Gastroenterology.

[53]  P. Borst,et al.  Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? , 2012, Open Biology.

[54]  Takanori Kanai,et al.  Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids , 2015, Nature Medicine.

[55]  Mari Mino-Kenudson,et al.  Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. , 2016, Cancer discovery.

[56]  Nancy R. Zhang,et al.  Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer , 2014, Genome Biology.

[57]  H. Clevers,et al.  Organoids as Model for Infectious Diseases: Culture of Human and Murine Stomach Organoids and Microinjection of Helicobacter Pylori. , 2015, Journal of visualized experiments : JoVE.

[58]  M. Spector,et al.  Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.

[59]  Olivier Gevaert,et al.  Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture , 2014, Nature Medicine.

[60]  D. Gary Gilliland,et al.  Drug development and clinical trials—the path to an approved cancer drug , 2012, Nature Reviews Clinical Oncology.

[61]  T. Litman,et al.  A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. , 2004, Cancer research.

[62]  Hans Clevers,et al.  Modeling Development and Disease with Organoids , 2016, Cell.

[63]  H. Clevers,et al.  Biased competition between Lgr5 intestinal stem cells driven by oncogenic mutation induces clonal expansion , 2013, EMBO reports.